NEUP

+ Watchlist + Portfolio

Neuphoria Therapeutics Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.93
52-Week Range: $3.19 – $21.40
Market Cap: $21.35M
P/E (TTM): —
EPS (TTM): -7.90
Dividend Yield: —

Advanced Metrics

Price/Book: 0.72
PEG Ratio: —
Return on Equity: -62.90%
Return on Assets: -27.97%
Gross Margin: 0.00%
Operating Margin: 110513.32%
Profit Margin: 0.00%
Current Ratio: 14.31
Debt/Equity: 0.00
Total Debt: $34.23K
Free Cash Flow: $-10.22M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.94M

NEUP Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$181.36K	$0.00	$0.00	—
Research & Development	$11.01M	$13.07M	$9.42M	—
Selling, General & Admin	$5.27M	$8.91M	$8.47M	—
Operating Expenses	$14.86M	$21.56M	$17.80M	—
Operating Income	-$14.68M	-$21.56M	-$17.80M	—
EBITDA	-$14.32M	-$20.90M	-$17.13M	—
Pretax Income	-$15.10M	-$21.52M	-$15.58M	—
Income Tax	-$131.95K	-$139.17K	-$87.32K	—
Net Income	-$14.97M	-$21.38M	-$15.49M	—
Diluted EPS	-0.17	-0.16	-0.12	-0.23
Diluted Shares	1.35B	122.39M	149.80M	1.62M

NEUP Income statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$662.72K	$15.00M	$0.00	$0.00	$0.00
Research & Development	$1.74M	$1.62M	$3.79M	$697.72K	-$518.17K
Selling, General & Admin	$2.63M	$1.41M	$1.87M	$2.13M	$1.69M
Operating Expenses	$4.06M	$3.03M	$5.65M	$2.35M	$827.28K
Operating Income	-$3.40M	$11.97M	-$5.65M	-$2.35M	-$827.28K
EBITDA	-$3.23M	$12.14M	-$5.49M	-$2.18M	-$661.59K
Pretax Income	-$1.93M	$11.18M	-$9.94M	$1.83M	-$539.86K
Income Tax	$11.61K	-$81.19K	-$34.79K	-$34.79K	-$34.79K
Net Income	-$1.94M	$11.26M	-$9.91M	$1.86M	-$505.06K
Diluted EPS	-1.79	6.55	-4.41	-0.77	-0.09
Diluted Shares	1.58M	1.72M	2.25M	4.54M	5.41M

NEUP Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$4.34M	$17.04M	$13.65M	$22.17M	$19.44M
Receivables	$35.56K	$24.59K	$1.76K	$1.11M	$1.61M
Current Assets	$4.40M	$17.09M	$13.95M	$23.39M	$21.66M
Total Assets	$18.17M	$30.71M	$27.34M	$36.60M	$34.81M
Current Liabilities	$2.13M	$1.55M	$5.12M	$2.59M	$1.51M
Total Debt	$199.40K	$172.46K	$118.22K	$33.47K	$34.23K
Total Liabilities	$4.42M	$4.72M	$14.83M	$6.90M	$5.39M
Retained Earnings	-$180.73M	-$169.46M	-$188.25M	-$186.39M	-$186.89M
Shareholders' Equity	$13.75M	$26.00M	$12.51M	$29.70M	$29.42M
Working Capital	$2.26M	$15.54M	$8.83M	$20.80M	$20.14M

NEUP Cash Flow statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$3.36M	$11.45M	-$3.79M	-$6.44M	-$3.34M
Free Cash Flow	-$3.36M	$11.45M	-$3.79M	-$6.44M	-$3.34M
Depreciation & Amortisation	$166.12K	$165.43K	$165.79K	$165.79K	$165.69K
Stock-Based Compensation	$19.08K	$19.68K	$111.28K	$93.70K	$70.29K
Financing Cash Flow	-$111.56K	$1.16M	$3.25M	$14.66M	$0.00
Net Change in Cash	-$3.47M	$12.62M	-$541.03K	$8.23M	-$3.34M

Market Snapshot

About

Neuphoria Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for neuropsychiatric disorders. The company focuses on innovative therapies for conditions such as depression, anxiety, and other mental health disorders using proprietary drug candidates and delivery mechanisms.